(Bloomberg) — The first pill to treat Covid-19 is on its way and vaccine producers are rolling out booster shots in wealthy countries. For investors, the next stage of the pandemic means a tougher landscape for stockpicking.
Most Read from Bloomberg
The success of Merck & Co.’s oral antiviral treatment in a clinical trial has shifted the momentum in the stock market, weighing on shares of the companies that developed the most effective vaccines, Moderna Inc. and the duo of Pfizer Inc. and…
Source link